Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8821 | 0.88 | — | — | |
| SCHEMBL29506231 | 0.88 | — | — | |
| Phosphine SCHEMBL27502321 | 0.86 | DYRK1A (0.45) | DYRK1AEGFR | |
| SCHEMBL4222803 | 0.86 | DYRK1A (0.45) | DYRK1AEGFR | |
| Bromide SCHEMBL26621962 | 0.86 | DYRK1A (0.45) | DYRK1AEGFR | |
| Iodide SCHEMBL1296857 | 0.86 | DYRK1A (0.45) | DYRK1AEGFR | |
| Ammonia Solution, Strong SCHEMBL28492555 | 0.86 | DYRK1A (0.45) | DYRK1AEGFR | |
| Hydrochloric Acid SCHEMBL18284548 | 0.86 | DYRK1A (0.45) | DYRK1AEGFR | |
| Acetamide SCHEMBL28053745 | 0.86 | DYRK1A (0.37) | DYRK1ANTRK1 | |
| Phosphoric Acid SCHEMBL12541220 | 0.85 | DYRK1A (0.39) | DYRK1ANTRK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2008134036-A1 | ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | DYRK1A 4838/4885NTRK1 4655/4885EGFR 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.